• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Covidien touts FDA clearance for “game-changing” Solitaire revascularization device

Covidien touts FDA clearance for “game-changing” Solitaire revascularization device

March 5, 2012 By MassDevice staff

Soltaire FR device

Covidien plc (NYSE:COV) won FDA clearance for its Solitaire FR revascularization device for removing blood clots and restoring blood flow in the brains of patients suffering acute ischemic stroke.

The federal watchdog agency cleared the device, which physically removes blood clots from vessels, on the basis of data gathered during Covidien’s Swift study, the first of its kind to compare mechanical interventions for acute ischemic stroke, according to a press release.

The company took a bit of a gamble in March 2011 when deciding to wrap up the Swift trial ahead of schedule with an eye toward speedy market approval, but the measure paid off with news of the FDA’s green light today.

"This new device heralds a new era in acute stroke care," principal investigator Dr. Jeffrey Saver said in prepared remarks. "We are going from our first generation of clot-removing procedures, which were only moderately good in reopening target arteries, to now having a highly effective tool. This really is a game-changing result."

The Swift studies began recruiting stroke patients in 2010, comparing the Solitaire system against Concentric Medical’s already-cleared Merci Retriever.

In a randomized study of 113 stroke patients at 18 hospitals, the Solitaire system showed a 2.5-fold benefit in restoring blood flow to the brain, a 1.7-fold improvement in post-stroke neurological function and effectively cut mortality rate in half at 90 days, according to a press release.

The company decided to stop enrolling new patients in the study after conferring with members of a Data Safety Monitoring Board, a panel of independent experts that recommended that the company take the trial data to the FDA right away, rather than wait for all 200 of the proposed participants in the study to be treated and tested.

Covidien saw a modest bump on Wall Street today, trading 18 cents higher at $52.14 as of about 12:45 p.m.

The Mansfield, Mass.-based medical products conglomerate acquired Solitaire as part of its $2.6 billion purchase of ev3 Inc. in 2010. The Solitaire device won CE Mark approval in the European Union in July 2009.

Stryker Corp. (NYSE:SYK) acquired rival stroke device maker Concentric in an all-cash $135 million deal in September 2011.

Filed Under: News Well, Vascular Tagged With: Concentric Medical Inc., Covidien, ev3 Inc., Stryker

More recent news

  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy